Triazine drug manufacturing services

This RFI is issued solely for information and planning purposes and does not constitute a solicitation. All information received in response to this RFI will be treated as business confidential information. Nonetheless, submitters should properly mark their responses if the information is confidential. Responses to the RFI will not be returned. Responses to this notice are not offers and cannot be accepted by the Government to form a binding contract.

Responders are solely responsible for all expense associated with responding to this RFI.

RFI Response and due date: 3/15/2017

Instructions to Responders:

Responses from all capable and qualified sources are encourgaged to respond to this request.

White papers should adhere to the following formatting and outline instructions:

1. All submissions shall be made electronically and be in one of the following formats: Microsoft Word or Adobe PDF.
2. Cover Page (1page)
• Title
• Organization
• Responders technical and administrative points of contact (names, addresses, phone, fax number and email addresses)
• Topic area(s) addressed

3. Please note that the response shall provide sufficient technical data to
determine how you fully meet the requriements as specified in the Peformance Work Statement.

Please note that responses are due no later than 15, March 2017. The preferred method of submission is via email. The point of contact for this action is Sharew Hailu, Contract Specialist Sharew.Hailu.civ@mail.mil. Only electronic responses are requested. No evaluation letters and/or results will be issued to the respondents. At this time no solicitation exists; therefore, please do not request a copy of the solicitation. NO PHONE CALLS PLEASE. It is the responsibility of any potential offeror to monitor this site for the release of any solicitation or synopsis.

Review attached document for a detailed listing of the requirement.